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ABSTRACT 23 
There is a limited understanding of the population pharmacokinetics (PK) and 24 
pharmacodynamics (PD) of amphotericin B deoxycholate (DAmB) for cryptococcal 25 
meningitis (CM). A PK study was conducted in n=42 patients receiving DAmB 1 mg/kg q24h. 26 
A 2-compartment PK model was developed. Patient weight influenced clearance and 27 
volume in the final structural model. Monte Carlo simulations estimated drug exposure 28 
associated with various DAmB dosages. A search was conducted for trials reporting 29 
outcomes of CM patients treated with DAmB monotherapy and a meta-analysis was 30 
performed.  31 
The PK parameter means (standard deviation) were: clearance, 0.03 (0.01) x weight 32 
+ 0.95 (0.02) litres/hour; volume, 0.89 (0.90) x weight + 1.54 (1.13) litres; first-order rate 33 
constant from central to peripheral compartment, 7.12 (6.50) hours-1; from peripheral to 34 
central compartment, 12.13 (12.50) hours-1. The meta-analysis suggested that DAmB dosage 35 
explained most of the heterogeneity in cerebrospinal fluid (CSF) sterility, but not in 36 
mortality outcomes. Simulations of area under concentration-time curve (AUC144-168) 37 
resulted in median (interquartile range) values 5.83 mg.h/litre (4.66-8.55), 10.16 (8.07-38 
14.55) and 14.51 (11.48-20.42), with dosages of 0.4, 0.7 and 1.0 mg/kg q24h respectively. 39 
DAmB PK is described adequately by a linear model that incorporates weight on 40 
clearance and volume. Inter-patient PK variability is modest and unlikely to be responsible 41 
for variability in clinical outcome. There is a discord between the impact that drug exposure 42 
has on CSF sterility and on mortality outcomes, which may be due to cerebral pathology not 43 
reflected in CSF fungal burden, in addition to clinical variables. 44 
 45 
  46 
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INTRODUCTION 47 
Cryptococcal meningitis is a leading infectious cause of morbidity and mortality 48 
worldwide, with approximately 223,100 incident cases and 181,100 deaths annually (1). The 49 
ten-week mortality for patients receiving the current standard-of-care is 24-31% (2-5). 50 
There have been no new antifungal agents developed for use in low-to-middle income 51 
countries in the last 3 decades.  Given the paucity of new agents, one important strategy for 52 
improving clinical outcomes is a better understanding and use of currently available 53 
compounds.   54 
Amphotericin B (AmB) is a polyene antifungal agent with broad spectrum activity 55 
against yeasts and moulds, as well as some parasites.  AmB was initially isolated from a 56 
streptomycete and described in 1955 (6). AmB was the first therapeutic option for 57 
treatment of lethal invasive fungal diseases such as cryptococcal meningitis (7, 8). 58 
Amphotericin B deoxycholate (DAmB) is the most potent formulation of AmB on a mg-mg 59 
basis (9, 10) and is a mainstay for the treatment of cryptococcal meningitis.   60 
Clinical studies have progressively examined escalating dosages of 0.4mg/kg q24h 61 
(11, 12), 0.7mg/kg q24h (13-15) and 1.0mg/kg q24h (5) of DAmB for cryptococcal 62 
meningitis. The primary motivation of these studies was identification of the dosage that 63 
induces maximal antifungal activity.  A regimen of 0.7 – 1.0 mg/kg q24h in combination with 64 
flucytosine for two weeks is currently recommended for induction therapy (16). Higher 65 
DAmB dosages are associated with increased rates of cerebrospinal fluid (CSF) sterilisation 66 
(2) and improved mortality (4, 5, 17). However, the broad clinical utility of DAmB is 67 
compromised by dose-limiting toxicities that include infusional reactions, phlebitis, 68 
nephrotoxicity and anaemia (18, 19).  A detailed understanding of the therapeutic index for 69 
each DAmB dosage level is lacking.  70 
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 Herein, we describe the development of a population pharmacokinetic model of 71 
DAmB.  In addition, a meta-analysis of clinical trials of DAmB monotherapy was performed 72 
to estimate the contribution of various DAmB dosages to the observed heterogeneity in 73 
study outcomes. Finally, Monte Carlo simulations were performed to estimate the mean, 74 
median and dispersion of drug exposures that are associated with microbiological and 75 
clinical outcomes from DAmB monotherapy. 76 
  77 
 o
n
 June 7, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
  5 
RESULTS  78 
Demographics 79 
A total of 42 patients (22 from Vietnam and 20 from Uganda) were recruited over an 80 
11-month period between January and November 2016.  Twenty two patients (52 %) were 81 
female. The overall median (range) age was 33 years (20 – 73 years), weight 48 kg (32 – 68 82 
kg) and body mass index 18 kg/m2 (12 – 25 kg/m2), creatinine at enrolment 69 µmol/L (37 – 83 
167 µmol/L) and estimated glomerular filtration rate using the Cockcroft Gault equation 84 
76.7 mL/min/1.73m2 (35.4 – 146.7 mL/min/1.73m2). The demographic data are shown by 85 
ethnicity and overall in Table 1. There were no statistically significant differences between 86 
ethnic groups in any demographic variable. 87 
 88 
Pharmacokinetic data 89 
 The final dataset included 282 of 312 total observations from the Vietnamese cohort 90 
and 197 of 241 total observations from the Ugandan cohort (mean 11.4 samples per 91 
patient, range 6-18). In total, 74 plasma samples were excluded because of absent 92 
information on the time PK samples were drawn. Figure 1 shows the raw plasma 93 
concentration-time profiles from study participants.  94 
 95 
Population pharmacokinetic models 96 
 Initial exploration of structural models revealed that a two-compartment model 97 
fitted the data better than a three-compartment model.  Specifically, the three-98 
compartment structural model resulted in a more negative log likelihood value (-55.5 versus 99 
-42.8) and higher AIC (127.3 versus 101.9).  Accordingly, subsequent model development 100 
was based on a two-compartment base model.  101 
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Model 1 was a standard two-compartment model without inclusion of covariates. 102 
Linear regressions of the Bayesian estimates of clearance and volume (derived from the 103 
mean population PK parameter values from Model 1) with weight and estimated glomerular 104 
filtration rate (eGFR) as covariates are presented in Figures 2a and 2b, respectively. A 105 
relationship was apparent between patient weight and both estimated clearance (slope 1.2, 106 
95% confidence interval for estimate of slope 0.51 to 1.88, p=0.002) and estimated volume 107 
of the central compartment, (slope 1.08, 95% CI 0.05 to 2.11; p<0.001).  Similarly, linear 108 
regression described a positive relationship between eGFR and estimated clearance (slope 109 
of linear regression 0.01, 95% CI for the slope 0 to 0.02, p<0.001) and volume (slope 0.67, 110 
95% CI 0.36 to 0.98, p<0.001). These covariates were incorporated into the structural model 111 
as follows: Model 2 incorporated weight as a covariate with a linear term for clearance; 112 
Model 3 incorporated weight as a covariate with a non-linear term for clearance and Model 113 
4 incorporated both weight and baseline renal function as covariates in the equations, with 114 
linear clearance.  Population PK parameter estimates for all 4 models are shown in Table 2.  115 
There were no statistically significant differences in estimated clearance and volume from 116 
the standard model (Model 1) according to ethnicity.  The mean (95% CI) clearance was 2.03 117 
litres/h (1.69 – 2.38) and 2.24 litres/h (1.91 – 2.56) for Vietnamese and Ugandan patients, 118 
respectively; p-value 0.37.  The mean (95% CI) volume was 33.55 litres (17.96 – 49.13) and 119 
63.93 litres (40.98 – 86.88) for Vietnamese and Ugandan patients, respectively; p-value 120 
0.09.   121 
 For all 4 two-compartment models the fit of the model to the data was acceptable.  122 
The model diagnostics are presented in Table 3.  The coefficient of determination of a linear 123 
regression of observed-versus-predicted plots after the Bayesian step was 0.72, 0.74, 0.69 124 
and 0.73 for Models 1, 2, 3 and 4, respectively.  The intercept and slope approximated 0 and 125 
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1 respectively for each regression (Table 3).  The mean parameter values predicted the 126 
observed values better than the medians. The measures of population bias and imprecision 127 
were comparable between the models, with bias -0.85, -0.34, -0.23 and -0.43 and 128 
imprecision 3.13, 2.97, 2.16 and 3.29 for Models 1, 2, 3 and 4 respectively. The more 129 
positive log likelihood value and lower Akaike information criterion (AIC) for Model 2 130 
implied that the inclusion of weight as a covariate explained a portion of the observed 131 
variance.  132 
The model that incorporated an exponential term for clearance (Model 3) decreased 133 
the log likelihood value and increased the AIC (Table 3).  The inclusion of eGFR in Model 4 134 
failed to increase the log likelihood value or reduce the AIC further.  In addition, there was 135 
no statistically significant difference between Model 1 and either Model 3 or Model 4; the 136 
latter models were therefore rejected. Model 2 was chosen as the final model.  Observed-137 
versus-predicted plots for the population and Bayesian posterior values in the final model 138 
are shown in Figure 3.  Figure 4 shows a visual predictive check (VPC) of the final model.  139 
 140 
Meta-analysis of clinical outcome data 141 
 Five clinical trials that included a DAmB monotherapy arm were identified. There 142 
was one trial in which 63 patients received 0.4 mg/kg q24h (11), 3 in which a combined 208 143 
patients received 0.7 mg/kg q24h (13-15) and 1 in which 99 patients received 1.0 mg/kg 144 
q24h (5). An additional study that reported clinical outcomes in untreated cryptococcal 145 
meningitis patients was also included. The baseline variables and clinical outcomes of these 146 
study arms are summarised in table 4. Due to the small number of studies, we were unable 147 
to adjust for baseline variables that may have had an impact on outcome measures (age, 148 
CD4 cell count, baseline level of consciousness, baseline fungal burden and baseline 149 
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cryptococcal antigenaemia). The forest plots of the dose-adjusted random effects model are 150 
shown in Figure 5. The model suggests that dose adjustment accounts for 77% of the 151 
heterogeneity in CSF sterility (p=0.007), but did not have a significant impact on the 152 
heterogeneity in either 2- or 10-week mortality outcomes (33%, p= 0.139 and 39%, p=0.092 153 
respectively).  154 
  155 
Monte Carlo simulations 156 
 Monte Carlo simulations (n = 5,000) were performed from the final population PK 157 
model. This enabled exploration of the consequences of the population PK variability, 158 
quantified in the final model, on plasma DAmB concentrations in a simulated population 159 
receiving the dosage regimens for which clinical trial outcome data were available. The 160 
median (interquartile range) AUC144-168 was 5.91 mg/L*h (4.96 – 9.33 mg/L*h) for patients 161 
receiving DAmB 0.4 mg/kg q24h, 10.21 mg/L*h (8.51 – 15.72 mg/L*h) for 0.7 mg/kg q24h 162 
and 14.61 mg/L*h (12.14 – 22.03 mg/L*h) for 1.0mg/kg q24h. The AUC144-168 distributions 163 
from the simulations are shown in Figure 6. 164 
 165 
  166 
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DISCUSSION 167 
 We conducted a PK study in HIV positive adults with cryptococcal meningitis in 168 
regions of high disease burden, and developed a population PK model that enabled the 169 
extent of interpatient variability to be quantified.  We described the PK of DAmB using a 2-170 
compartment PK model with i.v. infusion and first-order clearance of drug from the central 171 
compartment. Simulated AUCs reveal relatively modest PK variability, suggesting that the 172 
frequently poor clinical outcomes are not the result of significant PK variability.  The 173 
relationship between weight and drug clearance suggests that weight accounts for a portion 174 
of the observed variance.  Dosage adjustment on the basis of weight is necessary to ensure 175 
lighter patients are not over-dosed and heavier patients are not under-dosed.  However, the 176 
lack of impact of either eGFR or ethnicity on the PK suggests that dosage adjustment for 177 
these variables is not necessary to achieve comparable drug exposure across patient 178 
populations.  179 
The model-simulated median AUC of 10.17 mg.h/L following a regimen of 0.7 mg/kg 180 
q24h is consistent with AUCs estimated using non-compartmental techniques. For example, 181 
Bekersky et al calculated an AUC0-24 of 13.9 +/- 2 mg.h/L after 0.6 mg/kg i.v. in healthy 182 
volunteers (20). However, the simulations following 1mg/kg resulted in a median AUC of 183 
14.52 mg.h/L, which is considerably lower than that derived from a non-compartmental 184 
analysis (NCA) conducted by Ayestarán et al for the same dose administered to neutropenic 185 
patients (28.98 +/- 15.46 mg.h/L) (21). The reason for this is not immediately clear but may 186 
relate to physiological differences between these two critically unwell patient cohorts (22). 187 
Our meta-analysis of clinical outcomes from studies of DAmB monotherapy is limited 188 
by the fact that the included studies recorded CSF sterility at diverse time points ranging 189 
from 2 weeks (14) to 10 weeks (11). Nevertheless, the meta-analysis suggests that the 190 
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dosage of DAmB has a significant impact on the proportion of patients with sterile CSF and 191 
that achieving CSF sterility is dose-dependent up to 1mg/kg q24h. However, DAmB does not 192 
have a dose-dependent relationship with mortality at either 2 or 10 weeks.   193 
The potential reasons that DAmB dosage has a positive impact on CSF sterilisation, 194 
but not mortality are as follows: first, AmB toxicity may contribute to mortality (18, 19). 195 
Nephrotoxicity is dose-dependent and likely multifactorial. It is associated with 4.5 times 196 
increase in the odds of mortality from cryptococcal meningitis at 10 weeks (18). Free drug 197 
interacts with the distal tubules of the nephron causing increased monovalent ion delivery, 198 
with consequent afferent arteriolar constriction (23). Direct tubular toxicity results in 199 
hypokalaemia and hypomagnesaemia leading to cardiotoxicity (23, 24). Conversely, rapid 200 
infusion of AmB can result in extracellular shift of potassium, causing hyperkalaemia and 201 
cardiac dysrhythmias (25). Anaemia occurs in up to 75% of patients treated with DAmB as a 202 
result of direct suppression of erythropoiesis (23). Severe anaemia more than doubles the 203 
odds of 10-week mortality from cryptococcal meningitis (18). Secondly, mortality may be 204 
driven by factors not directly resulting from either disease or treatment.  For example, 205 
nosocomial bacteraemia may occur in up to 15-18% of patients hospitalised for cryptococcal 206 
meningitis (26). Third, fungal burden – and therefore conceivably, time to CSF sterility - is 207 
just one of multiple clinical variables associated with mortality in cryptococcal meningitis. 208 
Older age, altered mental status, low body weight, high peripheral white blood cell count 209 
and anaemia are independently associated with mortality at either 2 or 10 weeks (4). 210 
Immune reconstitution inflammatory syndrome (IRIS) remains a significant cause of 211 
mortality, occurring in 3-49% of cryptococcal meningitis patients surviving to initiation of 212 
antiretroviral treatment and carrying a mortality rate of up to 36% (17, 27). Raised 213 
intracranial pressure is an additional factor associated with mortality and at least 1 214 
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therapeutic lumbar puncture imparts a relative survival advantage of 69% in the first 10 215 
days of treatment (28). Finally, the trial cohorts included in the meta-analysis were from 216 
diverse sites in Africa, Asia, Europe and the USA. Factors such as health seeking behaviour 217 
and nutritional status may have influenced mortality outcomes. Our meta-analysis did not 218 
include any baseline factors besides DAmB dosage and we are therefore unable to identify 219 
whether they account for the heterogeneity in mortality that is not explained by DAmB 220 
dosage.  221 
The discordance between the influence that drug dosage has on CSF sterilisation and 222 
mortality is reflective of a growing consensus that CSF sterility is just one of many 223 
determinants of mortality in cryptococcal meningitis. A systematic review of 27 clinical trials 224 
determined that there was no correlation between CSF sterility at 2 weeks and all-cause 225 
mortality at either 2 or 10 weeks (29). The most biologically plausible explanation for this is 226 
that fungal burden in the CSF may not reflect the extensive encephalitis that is characteristic 227 
of cryptococcal meningitis (which is more accurately termed meningoencephalitis).  228 
Histopathological defects are more marked in patients co-infected with HIV; fungi 229 
accumulate in perivascular spaces, are deposited [predominantly extracellularly] in brain 230 
parenchyma, and form granulomatous cryptococcomas in brain tissue (30, 31). It is 231 
conceivable that brain parenchymal damage is a dominant determinant of mortality and 232 
that clearance of fungi in CSF is not mirrored by clearance in the cerebrum and other CNS 233 
subcompartments.  CSF sterility is an imperfect surrogate for the extent to which drug has 234 
penetrated to and sterilised the central nervous system. 235 
The meta-analysis suggests a strong dose-exposure-response relationship. Higher 236 
dosages are likely to be required to achieve efficacious drug exposure at the site of 237 
infection. DAmB has a large molecular weight (924 g/mol) and complex binding properties 238 
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(32). It does not readily penetrate the intact blood-brain barrier. Its concentration in 239 
meninges and cryptococcomas has been technically difficult to quantify in any finer detail 240 
than brain homogenates in preclinical models (33, 34). This challenge is compounded by a 241 
lack of clarity regarding the DAmB concentration required for therapeutic efficacy at the site 242 
of infection. Animal studies estimate that the cerebral concentration of DAmB at which the 243 
suppression of growth is half-maximal is 0.02 mg/litre in mice and 0.154 mg/litre in rabbits 244 
(33). AmB exposure above the level required to optimise antifungal activity appears only to 245 
contribute to toxicity (33, 35). Our simulations suggest that the optimal plasma AUC value in 246 
humans lies somewhere between 10-15 mg.h/L, though the information required to 247 
extrapolate this to cerebral DAmB concentrations is not currently available. The application 248 
of non-invasive, high-resolution technologies including Matrix-Assisted Lazer Desorption 249 
and Ionisation- Mass Spectroscopy Imaging (MALDI-MSI) is now possible, and offers the 250 
exciting potential to elucidate the PK/PD index associated with efficacy at the site of 251 
infection by enabling quantification of drug in specific cerebral sites, as has been 252 
demonstrated in murine models with gatifloxacin (36), doxycycline (37), pretomanid (38) 253 
and rifampicin (39). 254 
It may be the case that the maximal antifungal effect of DAmB is achieved with a 255 
dose of approximately 0.7 mg/kg, or slightly higher, and that gains made above this dose in 256 
terms of CSF sterility are offset by losses in terms of excessive toxicity. This may explain why 257 
significant increases in the proportion of patients achieving CSF sterility are not mirrored by 258 
reductions in mortality. The present analysis is not sufficient to more precisely define the 259 
optimal dosage of DAmB.  This is partly due to the lack of consensus regarding DAmB 260 
exposure targets.  We are unable to propose exposure targets based on our dataset, which 261 
does not include site-specific PK or detailed toxicodynamic data.  In addition, the 262 
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pharmacodynamic and clinical outcome data presented herein are derived from patient 263 
cohorts that are distinct from the patients that provided samples for the PK analysis.  DAmB 264 
monotherapy at dosages of 0.7 mg/kg q24h and 1.0 mg/kg q24h has not been directly 265 
compared in a randomised controlled trial. However, comparison of these dosages in 266 
combination with 5FC has been performed. Bicanic et al demonstrated increased early 267 
fungicidal activity with 1mg/kg q24h DAmB versus 0.7mg/kg q24h DAmB, both in 268 
combination with 5FC 100mg/kg/day in four divided dosages, but this was not reflected in 269 
reductions in mortality. A higher percentage of deaths was seen in the higher dose DAmB 270 
arm at both 2 weeks (9% versus 3%) and 10 weeks (26% versus 21%) but this was not 271 
statistically significant (p= 0.62 and 0.77 at 2 and 10 weeks, respectively) (2).   272 
In summary, these analyses suggest that the optimal dosage of DAmB for the 273 
treatment of cryptococcal meningitis lies between 0.7-1.0 mg/kg q24h. The precise drug 274 
exposure target that optimises clinical outcomes without producing significant toxicity 275 
remains to be defined. The extent of inter-individual PK variability in DAmB is modest and 276 
unlikely to account for the consistently poor clinical outcomes of cryptococcal meningitis.  277 
  278 
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MATERIALS AND METHODS 279 
Clinical Pharmacokinetic Studies 280 
Plasma samples were obtained from adults with HIV associated cryptococcal 281 
meningitis. Patients were initially recruited from a multicentre randomised controlled trial 282 
of adjuvant treatment with dexamethasone in HIV-associated cryptococcal meningitis 283 
reported elsewhere (n=3, International Standard Registered Clinical Number 59144167) 284 
(40). Following the early cessation of this trial, they were recruited from a prospective 285 
descriptive study at the same sites (n=39). Patients were recruited in 2 sites: The Hospital 286 
for Tropical Diseases in Ho Chi Minh City Vietnam, and Masaka General Hospital, Uganda. 287 
The study protocols were approved by the relevant institutional review boards and 288 
regulatory authorities at each trial site and by the Oxford University Tropical Research Ethics 289 
Committee.  290 
The protocol for the randomised controlled trial has been described previously (41). 291 
Briefly, patients had HIV infection, a syndrome consistent with cryptococcal meningitis, and 292 
laboratory evidence of cryptococcal infection. Patients who were pregnant, had renal 293 
failure, had gastrointestinal bleeding, had received more than 7 days of anti-cryptococcal 294 
antifungal therapy, were already taking corticosteroids, or required corticosteroid therapy 295 
for co-existing conditions were excluded. The inclusion and exclusion criteria for the 296 
prospective descriptive study were identical to those of the clinical trial.  Patients received 1 297 
mg/kg DAmB once daily by intravenous infusion over 5-6 hours, as well as 800mg 298 
fluconazole per day. Two patients recruited during the clinical trial received dexamethasone 299 
according to the following regimen: 0.3mg/kg/day intravenously (IV) for week 1, 300 
0.2mg/kg/day IV for week 2, then orally 0.1mg/kg/day for week 3, 3mg/day week 4, 301 
2mg/day week 5, 1mg/day week 6, then stop.  For the first five patients enrolled, blood 302 
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samples were obtained immediately prior to intravenous DAmB infusion, and then at 1, 2, 4, 303 
8, 12, 16, 20 and 24. The results for these patients informed a subsequent sampling strategy 304 
defined using optimal design theory such that patients were sampled pre-dose, then at 1, 2, 305 
4, 8, 12 and 24 hours after the initiation of infusion. PK sampling occurred on treatment 306 
days 1 or 2, and 7. Whenever patients had lumbar punctures performed for other clinical 307 
indications such as raised intracranial pressure, paired plasma samples were collected for 308 
subsequent PK analysis. Therefore, additional sparse samples were taken up to 17 days after 309 
initial dosing. Quantitative fungal counts were determined for each lumbar puncture, as 310 
described previously (15). 311 
 312 
Measurement of Amphotericin B Concentrations 313 
Amphotericin B concentrations in plasma were measured using high-performance 314 
liquid chromatography (HPLC) with a Shimadzu Prominence HPLC system (Shimadzu, Milton 315 
Keynes, UK).  Amphotericin B was extracted by protein precipitation.  A total of 300 µL of 316 
methanol that contained piroxicam 2 mg/L (Sigma Aldrich, Dorset, UK) as internal standard 317 
was added to 100 µL of matrix.  Samples were vortexed for 5 seconds and then centrifuged 318 
at 13,000 x g for 3 minutes.  319 
One hundred-fifty µL of supernatant was removed and placed in a 96-well plate, to 320 
which 50 µL of water was added.  A 50µL aliquot was injected onto a Kinetex 5µ XB-C18 321 
liquid chromatography column (Phenomenex, Macclesfield, UK).  Chromatographic 322 
separation was achieved using a gradient with the starting conditions of 75% A:25% B (0.1% 323 
formic acid in water as mobile phase A and 0.1% formic acid in acetonitrile as mobile phase 324 
B).  Mobile phase B was increased to 80% over five minutes and then reduced to starting 325 
conditions for two minutes of equilibration.  Amphotericin B and internal standard were 326 
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detected using UV detection at wavelengths of 406nm and 385nm; they eluted after 4.1 and 327 
4.6 minutes, respectively.  328 
The standard curve for amphotericin B encompassed the concentration range 0.05- 329 
8.0 mg/L and was constructed using blank matrix.  The limit of quantitation was 0.05 mg/L.  330 
The coefficient of variation was <9.3% over the concentration range 0.05-8 mg/L. The intra- 331 
and inter-day variation was <7.9%.  332 
 333 
Population Pharmacokinetic Modelling 334 
A PK model was fitted to the data using the non-parametric adaptive grid (NPAG) 335 
algorithm of the program Pmetrics (42) version 1.5.0 for R statistical package 3.1.1.  The 336 
data were weighted by the inverse of the estimated assay variance.  Both two- and three-337 
compartment models were tested, with zero-order intravenous input and first-order 338 
elimination from the central compartment.  The two-compartment model took the 339 
following form: 340 
a) 
𝑑𝑋(1)
𝑑𝑡
= 𝑅(1) − [
𝑆𝐶𝐿
𝑉
+ 𝐾12] ∗ 𝑋(1) +  𝐾21 ∗ 𝑋(2) 341 
b) 
𝑑𝑋(2)
𝑑𝑡
= 𝐾12 ∗ 𝑋(1) −  𝐾21 ∗ 𝑋(2) 342 
c) 𝑌(1) =
𝑋(1)
𝑉
 343 
Where equations (a) and (b) describe the rate of change of the amount of drug (mg) in the 344 
central and the peripheral compartments, respectively. X(1) and X(2) are the amount of 345 
amphotericin B in milligrams (mg) in the central (c) and peripheral (p) compartments 346 
respectively.  R(1) is the intravenous infusion of DAmB into the central compartment. SCL is 347 
the first-order clearance of drug (L/h) from the central compartment. V is the volume of the 348 
central compartment. K12 and K21 are the first-order inter-compartmental rate constants.  349 
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Equation (c) is the model output.  The three-compartment model contained an additional 350 
equation to connect the third compartment to the second compartment in series: 351 
d) 
𝑑𝑋(3)
𝑑𝑡
= 𝐾23 ∗ 𝑋(2) −  𝐾32 ∗ 𝑋(3) 352 
An initial condition was estimated to accommodate detectable drug in the first PK 353 
sample from those patients who received a dose of DAmB at an undocumented time before 354 
study enrolment. The non-zero initial conditions of X(1) and X(2) were estimated by 355 
assigning the respective parameters in the structural model (not shown in the equations 356 
above).  A switch was coded whereby a parameterised estimate of the initial condition was 357 
multiplied by a binary covariate equal to 1 where the first PK sample was drawn after a dose 358 
of DAmB, or 0 where this represented a pre-dose sample.  359 
 Once the standard model was fitted (Model 1), the effects of patient weight, 360 
baseline eGFR and patient ethnicity on the PK of DAmB were investigated.  Bidirectional 361 
stepwise multivariate linear regression of each subject’s covariates versus the Bayesian 362 
posterior parameter values revealed a significant (P< 0.05) relationship between both 363 
weight and eGFR with estimated PK parameters.  Univariate linear regression was 364 
employed, firstly to assess the relationship between patient weight and the Bayesian 365 
estimates for both clearance and volume.  Since a positive relationship was observed 366 
between weight and both PK parameters, the population PK model was re-fitted to the data 367 
(Model 2) with incorporation of the following equations to describe (e) clearance (SCL), and 368 
(f) volume (V), as functions of patient weight (Wt): 369 
e) 𝑆𝐶𝐿 = 𝐼𝑛𝑡_𝑐 + (𝑊𝑡 ∗ 𝑆𝑙_𝑐) 370 
f) 𝑉 = 𝐼𝑛𝑡_𝑣 + (𝑊𝑡 ∗ 𝑆𝑙_𝑣) 371 
Where Int is the intercept and Sl the slope of the linear regression describing the 372 
relationship between weight and clearance or volume, and the intercept and slope for each 373 
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of these PK parameters is parameterised separately. Thus, equation (a) of the structural 374 
model was replaced with: 375 
a.2)  
𝑑𝑋(1)
𝑑𝑡
= 𝑅(1) − [
𝐼𝑛𝑡𝑐+ (𝑊𝑡∗𝑆𝑙𝑐)
𝐼𝑛𝑡𝑣+ (𝑊𝑡∗𝑆𝑙𝑣)
 + 𝐾12] ∗ 𝑋(1) +  𝐾21 ∗ 𝑋(2). 376 
In addition, a power function was explored to describe the relationship between weight and 377 
clearance. In this model (Model 3), clearance was parameterised and scaled with weight to 378 
the exponent 0.75.  This exponent has previously been demonstrated to usefully scale for 379 
size (43, 44).  A linear relationship was maintained between volume and weight. Thus, in 380 
Model 3, equation (a) was replaced with:  381 
a.3)  
𝑑𝑋(1)
𝑑𝑡
= 𝑅(1) − [
𝑆𝐶𝐿 ∗  𝑊𝑡^0.75
𝑉∗𝑊𝑡
 + 𝐾12] ∗ 𝑋(1) +  𝐾21 ∗ 𝑋(2).  382 
Univariate linear regression was similarly employed to assess the relationship 383 
between eGFR and the Bayesian estimates for clearance and volume. A weaker but 384 
nevertheless positive association was demonstrated. Consequently, a further structural 385 
model was fitted to the data (Model 4), with the following equation (g) explored to describe 386 
clearance (SCL): 387 
g) 𝑆𝐶𝐿 = 𝐼𝑛𝑡_𝑐 + (𝑊𝑡 ∗ 𝑆𝑙_𝑐) ∗ (
𝑒𝐺𝐹𝑅
𝑚𝑒𝑑𝑒𝐺𝐹𝑅
) 388 
where eGFR is the estimated glomerular filtration rate calculated for each patient by the 389 
Cockcroft-Gault equation and med_eGFR is the population median estimated glomerular 390 
filtration rate.  In Model 4, equation (a) was replaced with: 391 
a.4)  
𝑑𝑋(1)
𝑑𝑡
= 𝑅(1) − [
𝐼𝑛𝑡𝑐+ (𝑊𝑡∗𝑆𝑙𝑐)∗(
𝑒𝐺𝐹𝑅
𝑚𝑒𝑑𝑒𝐺𝐹𝑅
)
𝐼𝑛𝑡𝑣+ (𝑊𝑡∗𝑆𝑙𝑣)
 + 𝐾12] ∗ 𝑋(1) +  𝐾21 ∗ 𝑋(2). 392 
To explore whether there were significant differences between the model predicted 393 
PK parameters in Vietnamese and Ugandan patients, Bayesian estimates of volume of 394 
distribution and clearance from the central compartment were compared using a Mann-395 
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Whitney test and a Student’s t-test respectively. Since no significant relationship between 396 
ethnicity and DAmB PK was apparent, this variable was not incorporated in the final model. 397 
The fit of the model to the data was assessed using a linear regression of observed-398 
versus-predicted values before and after the Bayesian step. The coefficient of determination 399 
of the linear regression was noted in combination with the intercept and slope of the 400 
regression for each model. Model comparison was achieved through calculation of the log-401 
likelihood value, the Akaike Information criterion (AIC), the mean weighted error (a measure 402 
of bias), and the bias-adjusted, mean weighted squared error (a measure of precision).  To 403 
verify the ability of the final model to predict observed concentrations with acceptable 404 
accuracy, a visual predictive check (VPC) of the data was performed.  For the VPC, the 405 
covariance matrix in Pmetrics was utilised to simulate 1000 patients administered DAmB on 406 
a mg per kg basis.  Simulated weight was limited to the range observed in our clinical 407 
cohort.  408 
 409 
Meta-analysis of clinical outcome data 410 
The pharmacodynamic data from patients enrolled in the present clinical trial are 411 
confounded by the co-administration of fluconazole (17).  Therefore, a search was 412 
performed for clinical trials of treatment for cryptococcal meningitis with at least one arm 413 
comprised of adult patients receiving DAmB monotherapy. For consistency, included trials 414 
were limited to those that recruited HIV-positive patients. Baseline clinical variables with 415 
demonstrated ability to predict patient mortality were selected a-priori and extracted from 416 
the studies; namely altered mental status, patient age and baseline CSF fungal burden (4, 417 
29). To aid meaningful trial comparison, baseline fungal burden and baseline CSF 418 
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cryptococcal antigen titre were extrapolated from one another where they were not 419 
explicitly reported in the study, applying a correlation presented by Jarvis et al (4).  420 
We collated a variety of clinical trial outcomes based on those that were commonly 421 
reported across trials of DAmB monotherapy: documented CSF sterility during trial follow-422 
up, mortality at 2 weeks and, where possible, mortality at 10 weeks.  Meta-analysis was 423 
performed on each outcome using a dose-adjusted random effects model to account for the 424 
baseline heterogeneity in the included studies. We included dose as a moderator variable in 425 
the model to assess the degree to which it explained heterogeneity in clinical outcome (45). 426 
The resulting mixed-effects model took the form: 427 
𝜃𝑖 = 𝛽0 + 𝛽1𝑑𝑜𝑠𝑒𝑖 + 𝑢𝑖  428 
where 𝛽0 and 𝛽1 are the model parameters intercept and dose respectively; 𝑑𝑜𝑠𝑒𝑖 is the 429 
dose given in the 𝑖th study, assuming study-specific random effects; and 𝑢𝑖~𝑁(0, 𝜏
2), 430 
where 𝜏2 is the amount of residual heterogeneity among the true effects 𝜃𝑖 that is not 431 
accounted for by dose. We calculated to what extent dose as a moderator influenced the 432 
true average effect, and estimated the corresponding proportions of each outcome 433 
measure. 434 
 435 
Monte Carlo Simulation  436 
Monte Carlo simulations were performed in Pmetrics (42).  Model 2 was used.  437 
Amphotericin B was administered on a mg/kg basis and infused over 5.5 hours.  The initial 438 
condition of the central and peripheral compartment was defaulted to zero.  The weight-439 
based dosage of DAmB was converted to an absolute dosage by multiplying by the 440 
simulated patient’s weight.  This process served to mimic the bedside drug administration in 441 
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the original clinical trial, in which dosing was planned on a mg/kg basis but the absolute 442 
dose that was ultimately administered was determined by the patient’s weight.  443 
Drug exposure was quantified using the DAmB AUC (9, 10, 46).  The simulated AUC 444 
for each patient was estimated 144 to 168 hours post therapy initiation.  Simulations were 445 
performed to estimate the AUC that resulted from dosages administered in clinical trials of 446 
DAmB monotherapy for which PD measures were available – specifically, 0.4, 0.7 and 447 
1.0mg/kg q24h (5, 11, 13-15). 448 
  449 
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Table 1: Patient demographics 641 
 642 
Demographic or clinical 
characteristic 
Vietnam Uganda Combined p-value for 
difference 
between 
Vietnam and 
Uganda 
Sex a (Male:Female) 12:10 8:12 20:22  
Age (years) b 
Mean 
Median 
Range 
 
38 
33 
20 - 73 
 
33 
33 
24 - 50 
 
36 
33 
20 - 73 
0.75† 
Weight (kg) c 
Mean 
Median 
Range 
 
47 
46 
32 - 68 
 
49 
49 
35 - 60 
 
48 
48 
32 – 68 
0.21† 
BMI (kg/m2) d 
Mean 
Median 
Range 
 
18 
18 
12 - 25 
 
18 
19 
15 - 22 
 
18 
18 
12 - 25 
0.73∆ 
Creatinine (µmol/L) a 
Mean 
Median 
Range 
 
71 
62 
37 – 167 
 
81 
79 
43 - 145 
 
75 
69 
37 - 167 
0.06† 
eGFR (ml/min/1.73m2) e 
Mean 
Median 
Range 
 
90.6 
89.8 
35.4 – 136.1 
 
79.3 
73.5 
49.8 – 146.7 
 
84.7 
76.7 
35.4 – 146.7 
0.19† 
a n = 42 643 
b n = 28 644 
c n = 39 645 
d n = 33 646 
e n = 26 647 
 648 
† Mann-Whitney test of significance 649 
∆ Unpaired t test of significance 650 
BMI: Body Mass Index; eGFR: estimated Glomerular Filtration Rate, by Cockcroft-Gault 651 
equation  652 
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Table 2:  Parameter estimates for the initial and modified two-compartment 653 
pharmacokinetic models 654 
 655 
Parameter and model Mean Median Standard deviation 
Model 1 
   
SCL (L/h) 2.19 2.46 0.77 
Vc (L) 27.77 13.88 28.06 
K12 (h-1) 3.84 2.16 6.57 
K21 (h-1) 1.14 0.32 3.06 
IC (mg) 10.16 2.55 9.00 
Model 2 
   
SCLslope (L/h/kg) 0.03 0.03 0.01 
SCLintercept (L/h) 0.67 0.57 0.01 
Vcslope (L/kg) 0.82 0.36 0.80 
Vcintercept (L) 1.76 1.99 1.29 
K12 (h-1) 5.36 3.83 6.76 
K21 (h-1) 9.92 0.46 12.27 
IC (mg) 20.29 6.03 27.75 
Model 3 
   
SCL (L/h/weight) 0.12 0.12 0.04 
Vc (L/weight) 1.40 0.51 1.75 
K12 (h-1) 1.69 0.50 4.09 
K21 (h-1) 8.31 0.27 12.32 
IC (mg) 30.10 7.87 40.56 
Model 4 
   
SCLslope (L/h) 0.01 0.01 0.01 
SCLintercept (L/h) 1.50 1.31 0.74 
Vcslope (L) 1.26 0.52 1.39 
Vcintercept (L) 1.64 0.01 2.96 
K12 (h-1) 3.86 0.73 7.74 
K21 (h-1) 11.24 0.40 13.44 
IC (mg) 26.15 6.17 26.76 
 656 
SCL: Clearance; Vc: Volume of distribution in central compartment; K12: first-order rate 657 
constant from the central to peripheral compartment; K21, first-order rate constant from 658 
peripheral to central compartment; IC: initial condition.  659 
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Table 3: Evaluation of the predictive performance of the initial and final model 660 
 661 
Model Log 
likelihood 
Number of 
cycles to 
convergence 
AIC Population 
bias 
Population 
imprecision 
Linear regression of observed-
predicted values for each patient 
 
R2, a Intercept Slope 
Model 1 -56.3 1137 124.8 -0.85 3.13 0.72 0.08 0.97 
Model 2 -42.8 1251 101.9 -0.34 2.97 0.74 0.01 1.01 
Model 3 -102.7 577 221.7 -0.23 2.16 0.69 0.00 1.04 
Model 4 -43.1 1704 102.7 -0.43 3.29 0.73 0.01 1.02 
 662 
Model 2 included a linear function to scale DAmB clearance to patient weight. 663 
Model 3 included a non-linear function to scale DAmB clearance to patient weight. 664 
Model 4 included a function to scale DAmB clearance to patient weight and eGFR. 665 
a Relative to the regression line fitted for the observed versus predicted values after the 666 
Bayesian step. 667 
 668 
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Table 4: Clinical outcomes from trial data of DAmB monotherapy, by dosing regimen 669 
 670 
DAmB 
regimen 
Location Number 
of 
patients 
Median 
age 
Median CD4 
cell count 
per mm
3
 
Reduced LOC 
at baseline, 
no./total no 
(%) 
Median 
baseline 
fungal 
burden, log10 
CFU/ml 
Baseline CSF 
CrAg titre, 
median 
Documented CSF 
sterility, no./total 
no (%)  
Mortality at 2 
weeks, 
no./total no 
(%) 
Mortality at 
10 weeks, 
no./total no 
(%) 
Percentage 
decrease 
haemoglobin, 
median 
(range) 
Hypokalaemia Reference 
No 
treatment 
Zambia 100 32 NR NR NR NR 0/100 (presumed) 65/100 (65) 100/100 (100) NR NR Mwaba et al, 
Postgrad Med J. 
2001 (47) 
0.4 mg/kg 
q24h 
USA 63 37 NR 16/63 (25) NR 1:512* 25/63 (40) 5/63 (8) NR; 9/63 at 12 
weeks (14%) 
NR NR Saag et al, 
NEJM 1992 (11) 
≈ 4.2 
0.7 mg/kg 
q24h 
Thailand 16 34 9 1/16 (6) 5.63 (5.19 – 
5.97) 
1:512 NR  2/16 (13) 3/16 (19) NR NR Brouwer et al, 
Lancet 2004 
(15) 
0.7 mg/kg 
q24h 
Australia/ 
The 
Nether-
lands 
13 41 35 2/13 (15) NR 1:256 3/8 (37) 0/13 (0) 2/13 (15) 20 (45-5) at 
10 weeks 
4/13 (31) 
<3mEg/L 
Leenders et al, 
AIDS 1997 (13) 
≈ 3.9 Fall in Hb 
>2g/dL: 2/13 
(15%) 
0.7 mg/kg 
q24h 
USA 179 37 18 18/179 (10) NR 1:1024 91/179 (51) 11/202 (5) NR NR in 
consistent 
way 
NR in 
consistent 
way 
Van der Horst 
et al, NEJM 
1997 (14) 
≈ 4.8 
1.0 mg/kg 
q24h 
Vietnam 99 28 18 31/97 (32) 5.91 (5.49 – 
6.48) 
NR 52/99 (53) 25/99 (25) 44/99 (44) All anaemia 
62/99 (63). 
Grade 3-4 
anaemia 
(<8g/dL): 
46/99 (46) 
All 54/99 (55). 
Gr 3-4 
(<2.5mmol/L): 
20/99 (20) 
Day et al, NEJM 
2013 (5) 
≈1:4096 
 671 
LOC: level of consciousness; no.: number; CFU: Colony Forming Units; NR: not reported; CSF: cerebrospinal fluid; CrAg: cryptococcal antigen. NEJM : New England Journal Of 672 
Medicine 673 
* Reported in (14). Italic text indicates value extrapolated from available data.674 
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Figure 1: Amphotericin B serum concentrations in 42 patients. 675 
[SEE ATTACHED FILE Figure 1] 676 
 677 
Patients received 1.0 mg/kg of amphotericin B deoxycholate (DAmB), infused over 5-6 678 
hours. 679 
  680 
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Figure 2: Linear regression of the relationship between (a) patient weight and (b) estimated 681 
glomerular filtration rate and Bayesian posterior estimates for clearance and volume of 682 
distribution. Circles are Bayesian estimates from each patient. Solid line: linear regression.  683 
 684 
 (a) 685 
[SEE ATTACHED FILE Figure2a_1] 686 
 687 
R2=0.32. Clearance = 0.05*weight – 0.2 688 
 689 
 690 
[SEE ATTACHED FILE Figure2a_2] 691 
 692 
R2=0.12. Volume = 1.08*weight – 24.8 693 
 694 
 695 
 696 
 697 
(b) 698 
[SEE ATTACHED FILEFigure2b_1] 699 
 700 
R2=0.17. Clearance = 0.01*weight + 1.03 701 
 702 
 703 
[SEE ATTACHED FILE Figure2b_2] 704 
 705 
R2=0.36. Volume = 0.67*weight – 31.13 706 
 707 
  708 
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Figure 3: Scatter plots showing observed versus predicted values for the chosen population 709 
pharmacokinetic model after the Bayesian step (model 2). 710 
 711 
 712 
R2=0.17  R2=0.74 713 
Intercept = 0.18 (95% CI 0.03 – 0.32)   Intercept = 0.01 (95% CI -0.04 – 0.07) 714 
Slope = 0.89 (95% CI 0.70 – 1.09)    Slope = 1.01 (95% CI 0.95 – 1.07) 715 
 716 
Circles, dashed lines, and solid lines represent individual observed-predicted data points, line of identity, and 717 
the linear regression of observed-predicted values, respectively. All observed and predicted amphotericin B 718 
concentrations in mg/L. AmB: Amphotericin B; CI: Confidence Interval. 719 
 720 
 721 
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Figure 4: Visual predictive check of the final model. 722 
[SEE ATTACHED FILE Figure4.tiff] 723 
 724 
The black circles indicate observed DAmB concentrations.  The continuous lines represent 725 
the 5th, 50th and 95th percentiles of DAmB concentrations in 1000 simulated patients.  In 726 
total, 83.4% of observed DAmB concentrations fall within the 5th and 95th percentiles 727 
estimated by the final model, indicating adequate model fit.  728 
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Figure 5: Meta-analysis of clinical trials of DAmB monotherapy showing dose adjusted 729 
effects on A) CSF sterility, B) Mortality at 2 weeks and C) Mortality at 10 weeks. 730 
 731 
A) 732 
[SEE ATTACHED FILE Figure5a.tiff] 733 
 734 
Tau value for unadjusted model: 4.22.  Tau value for dose-adjusted model: 0.98.  Dose adjustment accounts 735 
for (4.22 – 0.98)/4.22 = 77% of heterogeneity in clinical outcome. P-value for dose adjustment 0.007. 736 
 737 
 738 
 739 
B) 740 
[SEE ATTACHED FILE Figure5b.tiff] 741 
 742 
Tau value for unadjusted model: 1.90.  Tau value for dose-adjusted model: 1.28.  Dose adjustment accounts 743 
for (1.90 – 1.28)/1.90 = 33% of heterogeneity in clinical outcome. P-value for dose adjustment 0.14. 744 
 745 
 746 
 747 
C) 748 
[SEE ATTACHED FILE Figure5c.tiff] 749 
 750 
Tau value for unadjusted model: 9.0.  Tau value for dose-adjusted model: 4.93.  Dose adjustment accounts for 751 
(9.00 – 4.93)/9.00 = 45% of heterogeneity in clinical outcome. P-value for dose adjustment 0.07. 752 
 753 
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Figure 6: AUC distributions based on Monte Carlo simulations 754 
 755 
 756 
 757 
 758 
 759 
 760 
 761 
 762 
 763 
 764 
 765 
Simulated dosing regimens are 0.4, 0.7 and 1.0 mg/kg q24h. Medians, 25th and 75th percentiles displayed on each histogram (P25 and P75). 766 
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